Employees: 1,887
Size GuiZhou SanLi Pharmaceutical (603439.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $583M, the 3318th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥9.76 on 18 Nov 2026.
Performance Over six months the shares fell 19.8%, against -29.5% for the median peer and -20.0% for the China market (cap-weighted) — 4th highest of 20 in its peer set.
Growth Revenue fell 5.7% over the last twelve months (peer median -2.2%); the operating margin is 5.0% (peer median -2.3%).
Valuation It trades at 26.8× forward earnings against a peer median of 10.8× (4th most expensive of 9).
Price implies For today's price to make sense, revenue must grow about 21% a year for seven years (Req g). Recent delivered growth is +22%, so the hurdle is -1 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 4.0 points below its cost of capital (9.1% WACC).
Next results Next results expected around 28 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥1.64B | CN¥1.69B | CN¥2.13B | CN¥1.62B | CN¥1.19B |
| Revenue growth | — | -21% | +31% | +36% | — |
| Gross profit | CN¥1.20B | CN¥1.14B | CN¥1.44B | CN¥1.16B | CN¥843M |
| EBITDA | n/a | CN¥262M | CN¥400M | CN¥307M | CN¥222M |
| Net income | CN¥52.8M | CN¥46.3M | CN¥274M | CN¥293M | CN¥201M |
| Free cash flow | CN¥183M | CN¥139M | CN¥63.5M | CN¥169M | CN¥175M |
| Capital expenditure | CN¥22.9M | CN¥25.8M | CN¥45.2M | CN¥109M | CN¥120M |
| Total debt | CN¥668M | CN¥795M | CN¥728M | CN¥610M | CN¥235M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 603439.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -16.6% | -11.8% | 7th lowest of 20 |
| 6-month return | -19.8% | -29.5% | 4th highest of 20 |
| Distance from 52-week high | -44.1% | -43.9% | 10th lowest of 20 |
| Revenue growth (TTM) | -5.7% | -2.2% | 7th lowest of 17 |
| Operating margin | 5.0% | -2.3% | 6th highest of 15 |
| Forward P/E | 26.8× | 10.8× | 4th most expensive of 9 |
| Growth the price implies (Req g, 7 yrs) | 20.9% | -1.0% | 3rd most demanding of 10 |
| Growth delivered (Del g) | +21.9% | +2.8% | highest of 10 |
| Hurdle (Req g minus delivered) | -1.0 pp | +1.0 pp | 5th least demanding of 10 |
| ROIC minus cost of capital | -4.0 pp | -6.6 pp | 6th highest of 13 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| GuiZhou SanLi Pharmaceutical 603439.SS | China | $583M | -20% | -6% | 5% | 26.8× | 20.9% | +21.9% |
| Cullinan Therapeutics CGEM | United States | $585M | -37% | n/a | n/a | n/a | n/a | n/a |
| Lepu Biopharma 2157.HK | Hong Kong | $580M | -43% | +47% | 7% | 53.6× | n/a | n/a |
| Oneness Biotech 4743.TWO | Taiwan | $580M | -13% | +19% | -589% | n/a | n/a | n/a |
| Abbisko Cayman 2256.HK | Hong Kong | $578M | -39% | -83% | -520% | n/a | n/a | n/a |
| Beijing Tong Ren Tang Chinese Medicine 3613.HK | Hong Kong | $577M | -26% | -21% | 32% | 10.2× | -15.4% | +2.8% |
| Xiangxue Pharmaceutical 300147.SZ | China | $591M | -41% | +3% | -39% | n/a | 50.4% | -12.3% |
| Immix Biopharma IMMX | United States | $596M | -20% | n/a | n/a | n/a | n/a | n/a |
| Alumis ALMS | United States | $569M | -80% | -67% | -5,375% | n/a | n/a | n/a |
| JIANMIN PHARMACEUTICAL 600976.SS | China | $598M | -14% | -2% | 8% | 6.7× | -6.2% | +6.5% |
| Entera Bio ENTX | United States | $568M | +163% | -100% | n/a | n/a | n/a | n/a |
| Hangzhou Bio-Sincerity Pharma-Tech 301096.SZ | China | $602M | -38% | +5% | -30% | 54.0× | n/a | n/a |
| Shandong Jincheng Pharmaceutical 300233.SZ | China | $604M | -31% | +2% | 4% | n/a | -0.6% | -1.6% |
| DBV Technologies DBV.PA | France | $604M | -46% | n/a | n/a | n/a | n/a | n/a |
| Jenkem Technology 688356.SS | China | $563M | -30% | +52% | 11% | 30.2× | 36.4% | +11.2% |
| Zhong Zhu Healthcare 600568.SS | China | $562M | -22% | -6% | -34% | n/a | n/a | n/a |
| Chongkundang 185750.KS | South Korea | $609M | -27% | +6% | 4% | 11.4× | -6.6% | +5.4% |
| Luoxin Pharmaceuticals Group Stock 002793.SZ | China | $609M | -26% | -10% | -9% | n/a | -1.0% | -17.9% |
| Achieve Life Sciences QUIT | United States | $609M | n/a | n/a | n/a | n/a | n/a | n/a |
| HeiLongJiang ZBD Pharmaceutical 603567.SS | China | $610M | -39% | -82% | n/a | 5.4× | 9.1% | -25.1% |
| Tianjin Lisheng Pharmaceutical 002393.SZ | China | $557M | -24% | -3% | 7% | 9.0× | -5.8% | +4.1% |